Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 83 SUSTAIN trials with semaglutide SUSTAIN 1 2 3 4 5 6 7 Baseline 8.1% 8.1% 8.3% 8.2% 8.4% 8.7% 8.2% 0.0 -0.1 Change in HbA1c (%) Baseline -0.5 -0.8 -0.9 -1.1* -1.3* -1.6* -1.5* -1.6* -1.5* -1.2* -1.4* -1.4* -1.6* -1.8* 1.2 92 kg 89 kg 96 kg 93 kg 92 kg Change in weight (kg) -3.7* -4.5* -1.0 -1.9 -1.9 -4.3* -5.6* -6.1* -5.2* -3.5* -1.4 -0.4 -1.1 -1.3 -1.5* -1.8* 92 kg 95 kg -0.6 -3.7* -3.6* -4.9* -4.6* -2.3 -3.0 semaglutide 1 mg semaglutide 0.5 mg Placebo¹ sitagliptin 100 mg -6.4* exenatide ER glargine U100 -6.5* Dulaglutide 1.5 mg * Statistically significant; SUSTAIN 1: QW sema versus placebo in drug-naïve subjects with T2D; SUSTAIN 2: QW sema versus sitagliptin 100 mg once-daily in subjects with T2D added on to 1-2 OADs; SUSTAIN 3: QW sema versus QW exenatide ER 2.0 mg in subjects with T2D added on to 1-2 OADS; SUSTAIN 4: QW sema versus QD insulin glargine in subjects with T2D added on to 1-2 OADs; SUSTAIN 5: QW sema versus placebo in subjects with type 2 diabetes added to insulin; SUSTAIN 6: QW sema versus placebo, added to standard-of-care; SUSTAIN 7: QW sema versus QW dulaglutide 75 mg and 150 mg in subjects with T2D added on to 1-2 OADS ER: Extended-release; QW: once weekly; QD: once daily; sema: semaglutide; T2D: type 2 diabetes, OAD: oral anti-diabetics Dulaglutide 0.75 mg novo nordisk

View entire presentation